Hydroxycarbamide (Xromi) 100 mg/ml oral solution recommended as an option for restricted use within NHS Wales for prevention of vaso-occlusive complications of sickle cell disease

Xromi, the first licensed oral liquid formulation of hydroxycarbamide, is restricted for use in patients over two years of age who are unable to swallow the capsules.

All Wales Medicines Strategy Group